Updates in regulatory guidelines to blood pressure monitoring in clinical trials webinar
As regulatory bodies increase demands on drug manufacturers to study pressor effects of medications, it’s important to understand ABPM monitoring as a safety measure for chronic drug intake. But monitoring blood pressure effects in clinical trials can be challenging not only to the patient but to the sponsor as well.
Join our panel of cardiologists at an upcoming webinar, “Updates in Regulatory Guidelines to Blood Pressure Monitoring in Clinical Trials”, on April 27th at 11am EST, where you can gain insights on the new draft guidance, and how to reduce data variability and increase patient compliance in blood pressure monitoring. The discussion will be held by experts Robert Kleiman, MD, Vice President, Cardiology and Chief Medical Officer, Todd Rudo, MD, Deputy Chief Medical Officer, Cardiac Safety, Jeff Heilbraun, MS, Medical and Scientific Affairs, and moderated by Borje Darpo, MD, PhD, Chief Scientific Advisor of Cardiac Safety.
Speakers
Robert Kleiman, MD
Vice President Cardiology & Chief Medical Officer at Clario
Dr. Robert Kleiman is a cardiac electrophysiologist who has performed research in both basic cellular electrophysiology as well as clinical electrophysiology. Dr. Kleiman trained at the University of Pennsylvania and practiced clinical cardiology for 12 years before joining Clario in 2003. Dr. Kleiman currently oversees all of Clario’s cardiology services, consulting with external clients and providing cardiac safety regulatory advice.
Todd Rudo, MD
Vice President, Cardiology and Deputy Chief Medical Officer at Clario
Dr. Todd Rudo is the Deputy Chief Medical Officer at Clario, with board certifications in cardiology, cardiac electrophysiology, nuclear cardiology, and adult echocardiography. He completed his general medical training at Jefferson Medical College in Philadelphia, PA, and specialty training at Lankenau Medical Center in Wynnewood, PA. After transitioning from private practice, Dr. Rudo has focused his career on drug safety / pharmacovigilance with responsibilities across multiple therapeutic areas within large and medium-size pharmaceutical companies. In his current role, he primarily supports cardiac safety consultative services, in addition to oversight of ECG core lab activities.
Jeff Heilbraun, MS
Vice President, Medical and Scientific Affairs, Cardiac Safety at Clario
Jeffrey Heilbraun attended Tufts University in Boston, Massachusetts where he completed his Bachelor of Science degree in Biology with a focus on physiology. Jeff continued his studies at the American University in Washington D.C., receiving a fellowship and completing his Master of Science in Health Promotion and Disease Management. He was employed at the American University as an adjunct professor in the Health Promotion program. Throughout his career, Jeff has maintained his focus on the science, technology, trial design and regulatory considerations surrounding cardiac safety (ECG and blood pressure endpoints) within pharmaceutical development, with a special interest in hemodynamics. He has supported publications in cardiac safety considerations in oncology drug development and the regulatory considerations for “off-target” blood pressure response in compound development.
Borje Darpo, MD, PhD
Chief Scientific Advisor at Clario
As Clario’s Chief Scientific Advisor, Borje Darpo, MD, PhD oversees Clario’s cardiology services and consults with external customers to ensure the cardiac safety of their compounds in development. He is board certified in cardiology and internal medicine and has 20 years of experience overseeing projects across all phases of clinical development.